ICI conference 2017: new preclinical data further strengthen the rationale of IPH5401 and monalizumab for cancer treatments and in combination with anti-PD-1/PD-L1
Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102
Innate Pharma strengthens its proprietary pipeline with the acquisition of anti-C5aR, a first-in-class clinical-stage antibody,from Novo Nordisk A/S
IPH4102: Completion of the dose escalation part of the Phase I trial - Data to be presented at International Conference on Malignant Lymphoma in June 2017 in Lugano
Expansion of Phase I/II trial evaluating lirilumab in combination with Opdivo (nivolumab) in patients with advanced solid tumors
Clinical and preclinical data on monalizumab to be presented at AACR annual meeting 2017
Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia
Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb for continued exploration of lirilumab in combination with Opdivo
Further clinical data for lirilumab and IPH4102 presented at ASH annual meeting reinforcing confidence in our programs
First clinical data for monalizumab as a single agent in cancer patients show favorable safety profile
